These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1384153)

  • 1. [Can mepartricin be considered an antiandrogenic drug?].
    Lubrano C; Bianchi P; Verna T
    Minerva Urol Nefrol; 1992; 44(2):113-6. PubMed ID: 1384153
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of treatment with mepartricin on the concentrations of androgen receptors in adenomatous human prostatic tissue. Preliminary data].
    Longo A; Fiorelli G; Rizzo M; Tosto A; Natali A; Forti G
    Minerva Urol Nefrol; 1988; 40(2 Suppl):13-5. PubMed ID: 2460937
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapeutic usefulness of mepartricin in benign prostatic hypertrophy: 2 years' experience. Preliminary note on the effect of mepartricin on certain possible etiopathogenic factors in benign prostatic hypertrophy].
    Mirone V; Prezioso D; Palmieri A; Bocchini P
    Minerva Urol Nefrol; 1988; 40(2 Suppl):16-7. PubMed ID: 2460938
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytoplasmic and nuclear androgen receptor content of normal and neoplastic human prostates and lymph node metastases of human prostatic adenocarcinoma.
    Shain SA; Boesel RW; Lamm DL; Radwin HM
    J Clin Endocrinol Metab; 1980 Apr; 50(4):704-11. PubMed ID: 6154061
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of mepartricin on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats.
    Re G; Badino P; Odore R; Vigo D; Bonabello A; Rabino S; Capello F; Bruzzese T
    Pharmacol Res; 2001 Aug; 44(2):141-7. PubMed ID: 11516265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of treatment with mepartricin on the plasma androgen and gonadotropin concentrations in subjects with benign prostatic hypertrophy].
    Sciarra F; Bianchi P; Toscano V
    Minerva Urol Nefrol; 1988; 40(2 Suppl):10-2. PubMed ID: 2460936
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of two different medical treatments on dihydrotestosterone content and androgen receptors in human benign prostatic hyperplasia.
    Petrangeli E; Sciarra F; Di Silverio F; Toscano V; Lubrano C; Conti C; Concolino G
    J Steroid Biochem; 1988; 30(1-6):395-9. PubMed ID: 2455099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replacement of surgical castration by GnRH inhibition for rat prostate androgen receptor preparations.
    Ashby J; Lefevre PA
    J Appl Toxicol; 2001; 21(5):353-4. PubMed ID: 11746178
    [No Abstract]   [Full Text] [Related]  

  • 9. Binding of mepartricin to sex hormones, a key factor of its activity on benign prostatic hyperplasia.
    Barone D; Peroglio F; Toso E; Bruzzese T
    Arzneimittelforschung; 2001; 51(12):984-90. PubMed ID: 11799846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hormonal therapy for benign prostatic hyperplasia].
    Sakai H; Kanetake H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical pharmacologic aspects of mepartricin. Possible pharmacologic interference with digitaloids and anticoagulants].
    Costa FV
    Minerva Urol Nefrol; 1988; 40(2 Suppl):5-6. PubMed ID: 2460951
    [No Abstract]   [Full Text] [Related]  

  • 12. Androgen receptor content of normal and hyperplastic human prostate.
    Trachtenberg J; Bujnovszky P; Walsh PC
    J Clin Endocrinol Metab; 1982 Jan; 54(1):17-21. PubMed ID: 6172440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Latest contribution concerning the use of mepartricin in adenoma of the prostate].
    Comar OB; Di Rienzo A
    Minerva Urol Nefrol; 1988; 40(2 Suppl):30-2. PubMed ID: 2460944
    [No Abstract]   [Full Text] [Related]  

  • 14. [Urination disorders, endocrine features and sexual activity in patients with benign prostatic hypertrophy under treatment with mepartricin].
    Scarpa RM; Migliari R; De Lisa A; Campus G; Usai E
    Minerva Urol Nefrol; 1988; 40(2 Suppl):18-20. PubMed ID: 2460939
    [No Abstract]   [Full Text] [Related]  

  • 15. Androgen receptor in human liver: characterization and quantitation in normal and diseased liver.
    Eagon PK; Elm MS; Stafford EA; Porter LE
    Hepatology; 1994 Jan; 19(1):92-100. PubMed ID: 8276373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mepartricin in the treatment of benign prostatic hyperplasia].
    Cirillo Marucco E; Pagliarulo A; Piccinno A; Di Rienzo U
    Minerva Urol Nefrol; 1988; 40(2):101-4. PubMed ID: 2459784
    [No Abstract]   [Full Text] [Related]  

  • 17. [Mepartricin versus placebo in the therapy of prostatic hypertrophy].
    Fini M; Perrone A; Ferraresi R; Salvi G; Misuriello G; Vagliani GF
    Minerva Urol Nefrol; 1988; 40(2 Suppl):53-4. PubMed ID: 2460953
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of mepartricin, a polyene macrolide agent, on fecal excretion and serum concentration of estrogen and number of prostatic estrogen receptors in immature rats.
    Shakutou S; Bandoh K; Yoshinaka Y; Kobayashi H; Yamanaka H
    Prostate; 1999 Jan; 38(1):17-27. PubMed ID: 9973105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the objective efficacy of mepartricin in benign prostatic hypertrophy].
    Cirillo Marucco E; Giocoli Nacci G; Pagliarulo A; Balacco G; Ludovico G
    Minerva Urol Nefrol; 1988; 40(2 Suppl):23-4. PubMed ID: 2460941
    [No Abstract]   [Full Text] [Related]  

  • 20. Tamoxifen decreases progesterone and nuclear androgen receptors in the human prostate.
    Albert JD; Geller J; Liu JD; Faber LE
    J Steroid Biochem; 1984 Dec; 21(6):659-62. PubMed ID: 6084754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.